Search

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

Registration & accommodation

Registration is now closed

Individual registrationHybrid registration includes:

In-person access to the scientific and educational sessions of the meeting
Access to the virtual platform
Meeting materials
Coffee/tea breaks on February 9-11, 2023 and lunches on February 10 & 11
Access to the Welcome Reception
Access to the…

Read more

Getting started

Sign up via the portal, with a user name and valid email address. Please use your official credentials to sign up. Once you’ve signed up, you’ll be asked to verify your email address.

Read more

EHA Mentorship Program eligibility

Before applying for the EHA Mentorship Program, please consider the eligibility criteria on this page. You should also read our policy on life events.

Read more

Support opportunities

View the EHA Ranking for 2025

EHA thrives on the support of the biomedical industry and the medical profession. The variety of opportunities available for industry range from educational activities to the EHA Congress.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more